Previous 10 | Next 10 |
Buying Penny Stocks on June 28th? Here’s What You Need to Know Finding penny stocks that are worth buying can be challenging. And despite there being a lot of positive movement in the past few trading days, the overall characterization of the stock market right now is bearish. Th...
Gainers: NeuroSense Therapeutics NRSN +83%. Axsome Therapeutics (AXSM) +37%. Agile Therapeutics (AGRX) +31%. GreenLight Biosciences (GRNA) +26%. Femasys (FEMY) +11%. Losers: GeoVax Labs GOVX -14%. SIGA Technologies (SIGA) -14%. Eargo (EAR) -12%. BioAtla...
There are plenty of catalysts in the stock market this week that could impact the future of investors for the rest of 2022. Critical economic data will be a bellwether for the next move. In the meantime, there’s likely to be no shortage of stock market volatility. This is where penny...
Axsome Therapeutics (AXSM) +50%as FDA issues proposed labeling for depression drug. Agile Therapeutics (AGRX) +42%. Nutex Health (NUTX) +14%announces that it has been selected to join both the RUSSELL 2000® AND RUSSELL 3000® INDEXES. Femasys (FEMY) +16%. Siyata Mobile (SYTA) +1...
PRINCETON, N.J., May 17, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced that Al Altomari, Chairman and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference taking place May 23-May 26, 2022 i...
Gainers: Data Storage Corporation (DTST) +40%. Indonesia Energy Corporation (INDO) +30%. Harpoon Therapeutics (HARP) +28%. Pulse Biosciences (PLSE) +24%. Praxis Precision Medicines (PRAX) +24%. Xeris Biopharma Holdings (XERS) +24%. Griffon Corporation (GFF) +22%. New Concept Energy (GBR) +20%...
Image source: The Motley Fool. Agile Therapeutics (NASDAQ: AGRX) Q1 2022 Earnings Call May 12, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Agile Therapeutics (AGRX) Q1 2022 Earnings Call Transcript
Agile Therapeutics, Inc. (AGRX) Q1 2022 Results Conference Call May 12, 2022 4:30 PM ET Company Participants Matt Riley - Head, IR Al Altomari - Chairman, CEO Dennis Reilly - CFO Conference Call Participants Oren Livnat - H.C. Wainwright Presentation Operator Good afternoon, and welcome to th...
Agile Therapeutics press release (NASDAQ:AGRX): Q1 GAAP EPS of -$3.78 beats by $2.22. Revenue of $1.76M (+1366.7% Y/Y) beats by $0.54M. Shares +4.85%. “We produced another quarter of double-digit growth in key prescription data for Twirla while also increasing revenue and reducing cash...
Twirla Experienced Another Quarter of Double-Digit Demand Growth in First Quarter 2022 Twirla Business Plan Progressing Company Anticipates Future 2022 Quarterly Operating Expenses to be Lower Management to Host Conference Call Today, Thursday, May 12, 2022 at 4:30...
News, Short Squeeze, Breakout and More Instantly...
Agile Therapeutics Inc. Company Name:
AGRX Stock Symbol:
NASDAQ Market:
Agile Therapeutics Inc. Website:
First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023 Twirla First Quarter 2024 Demand Rebounded 18% from Fourth Quarter 2023 PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Pink: AGRX), a women's healthcare com...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 ...